- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
argenx NV ADR(ARGX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ARGX
11/13/2026: ARGX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
argenx NV ADR is a commercial-stage global biopharmaceutical company specializing in antibody-based therapies for severe autoimmune diseases. The company's primary business strength is anchored by the successful global rollout of VYVGART, which has captured a leading position in precision immunology. Its main growth opportunity lies in label expansions across new indications and advancing a rich clinical pipeline under its Vision 2030 goals. Key risks include high product revenue concentration, heavy R&D expenditure, and emerging competition in the FcRn inhibitor space. The stock is best suited for growth-oriented investors willing to monitor clinical readouts and regulatory milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Rapid multi-year revenue scaling and a broad pipeline targeting major immunological conditions align well with growth mandates. |
| Momentum investor | Strong fit while signal remains positive | High trading volume and sharp reactions to clinical catalysts and sales reports attract active momentum participants. |
| Value investor | Weak fit | Trading at high forward multiples reflecting aggressive growth expectations limits traditional deep-value appeal. |
| Dividend investor | Weak fit | The company retains earnings to fund research and does not pay a regular dividend. |
| Low-risk investor | Mixed fit | High stock price volatility and binary clinical trial risks pose challenges for conservative capital preservation. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech market sentiment and clinical trial headlines regularly induce sharp stock price swings. |
| Valuation risk | Medium / high | Lofty valuation multiples leave little room for operational execution missteps or pipeline setbacks. |
| Competition risk (FcRn and targeted biologic rivalry) | Medium / high | Rival firms are advancing competing therapies that could threaten long-term market share dominance. |
| Business quality | Strong | Proprietary technology, robust gross margins, and proven commercial execution reflect high structural quality. |
| Dividend income | Low / none | No cash distribution is provided, making the stock unsuitable for income-focused strategies. |
| Execution risk | Medium | Successful execution of broad global clinical trials and new product launches is critical to meeting long-term targets. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 60.37B USD | Price to earnings Ratio 33.25 | 1Y Target Price 1144.74 |
Price to earnings Ratio 33.25 | 1Y Target Price 1144.74 | ||
Volume (30-day avg) 469.7K shares | Beta -0.06 | 52 Weeks Range 661.85 - 1072.75 | Updated Date 11/15/2026 |
52 Weeks Range 661.85 - 1072.75 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 28.87 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 60.6% | Avg. Invested days 56 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercial Immunotherapy Sales (VYVGART & VYVGART Hytrulo) | Global sales of efgartigimod formulations prescribed for severe autoimmune indications across the United States, Europe, Japan, and other regions. | Virtually all current revenues come from the commercial success and expanding adoption of VYVGART. |
| Collaboration and License Agreements | Upfront payments, milestone fees, and royalties generated from codevelopment partnerships using argenx's antibody platforms. | Secondary revenue stream that validates proprietary drug discovery platforms through partnerships with other drug makers. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-22 | When Before Market | Estimate 7.44 | Actual 7.8 |
Profitability
Profit Margin 31.73% | Operating Margin (TTM) 31.94% |
Management Effectiveness
Return on Assets (TTM) 11.64% | Return on Equity (TTM) 23.64% |
Valuation
Trailing PE 33.25 | Forward PE 28.82 | Enterprise Value 55.90B | Price to Sales(TTM) 10.21 |
Enterprise Value 55.90B | Price to Sales(TTM) 10.21 | ||
Enterprise Value to Revenue 9.6 | Enterprise Value to EBITDA 29.38 | Shares Outstanding 62.89M | Shares Floating 1.56B |
Shares Outstanding 62.89M | Shares Floating 1.56B | ||
Percent Insiders 0.04 | Percent Institutions 46.38 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

